摘要
目的:测定吉非罗齐的体内过程,作出相对生物利用度评价,为临床合理用药提供依据.方法:8名健康受试者交叉口服单剂量古非罗齐片和胶囊后,用HPLC法测定不同时间的血药浓度,经MCPKP软件拟合处理,并计算药物动力学参数.结果:吉非罗齐片和胶囊均符合开放一室模型,T_(max),C_(max),AUC_(0～∞)分别为(1.61±0.49)和(1.66±0.47)h,(37.28±9.71)和(29.97±5.58)μg/ml;(128.48±24.36)和(119.55±19.48)μg/(h·ml).结论:吉非罗齐片剂对胶囊剂的相对生物利用度为107.26%.
AIM:To study pharmacokinetics and bioavailability of gemfibrozil in 8 young healthy volunteers. METHODS: Acoording to the cross - over design,each volunteer was o-rally given gemfibrozil tablets and capsule in single dosage respectively,and the plasma concentrations in different time were determined by reversed-phase high-performance liquid method. RESULTS :The data were fitted by MCPKP program. The pharmacokinetics of gemfibrozil tablets and capsule could be described by open single compartment model. The Tmax, Cmax and AUCo~∞ of two products were (1. 61±0. 49)and (1. 66±0. 47)h,(37. 28±9. 71)and (29. 97±5. 58μg/ml;(28. 48±24. 36)and (119. 55±19. 48>μg/(h · ml) respectively. CONCLUSION: The relative bioavailiability of gemfibrozil talbets were 107-26% compared with capsule.
出处
《中国临床药学杂志》
CAS
1998年第1期12-15,共4页
Chinese Journal of Clinical Pharmacy
关键词
吉非罗剂
片剂
胶囊
高效液相色谱
药物动力学
gemfibrozil tablet
gemfibrozil capsule
high-performance liquid chro-matography
pharmacokinetics
relative bioavailability
